U.S. markets closed

Puma Biotechnology, Inc. (PBYI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.6500-0.0300 (-1.12%)
At close: 04:00PM EDT
2.6200 -0.03 (-1.13%)
After hours: 04:38PM EDT

Puma Biotechnology, Inc.

10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
424 248 6500

Full Time Employees192

Key Executives

NameTitlePayExercisedYear Born
Mr. Alan H. AuerbachFounder, Chairman, Pres, CEO & Sec.1.74MN/A1970
Mr. Maximo F. NouguesCFO & Principal Accounting Officer781.47kN/A1969
Dr. Alvin F. Wong Pharm.d.Chief Scientific Officer809.69kN/A1953
Mr. Douglas Hunt B.Sc., FRAPSSr. VP of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law632.65kN/A1965
Mr. Jeffrey Jerome LudwigChief Commercial Officer916.85kN/A1966
Mr. Mariann OhanesianSr. Director of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Corporate Governance

Puma Biotechnology, Inc.’s ISS Governance QualityScore as of September 1, 2023 is 5. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.